Article Sidebar

Submitted
May 7, 2019
Accepted
January 23, 2020
Published
April 30, 2020
Download
PDF EC (Bahasa Indonesia) Untitled (Bahasa Indonesia) Untitled (Bahasa Indonesia)
Statistic
Read Counter : 715 Download : 665

Main Article Content

Abstract

Background: Uses of HbA1c compared with glycated albumin as an indicator of glycemic control for hemodialysis patients(HD) needs to be evaluated. HbA1c has some limitations when used for HD because its results can falsely low or falsely high. It can be missunderstood if clinicians use HbA1c as glycemic control.
Objective: This study aimed to evaluate correlation between HbA1c and GA in HD patients with Diabetes Mellitus (DM).
Methods: This study was a cross sectional study conducted on November 2016 until January 2017. Its samples were obtained from 43 patients in HD with DM, fullfilling inclusion and exclusion criteria, located in a private hospital at east Jakarta. The HbA1c was measured by using a turbidimetric inhibition immunoassay method, and the GA was measured by using an enzimatic colorimetric method. In addition, a test of Pearson correlation was used to determine the correlation between HbA1c and GA with a significance of p<0.05.
Results: Averages of patients age in this study was 57.16 ± 9.0 years old, including 24 men (55.8%) and 19 women (44.2%). The mean values of HbA1C were 8 ± 2.30%, and the mean values of GA were 30.02 ± 13.3%. The mean duration of the HD was 4.5 ± 1.3 years. The glycemic control based on GA was significantly better than the HbA1c with p = 0.028 (Chi-Square test). Pearson correlation showed that there were a significant correlation between HbA1c and GA with r = 0.759 and p = 0.000.
Conclusion: There were a significant correlation between HbA1c with GA in HD patients with DM. Glycemic control based on GA was better than HbA1c.

Keywords

glycated albumin HbA1c diabetes mellitus hemodialysis HbA1c Glycated Albumin Diabetes Melitus Hemodialisa

Article Details

Author Biography

Pusparini Pusparini, Department of Clinical Pathology, Faculty of Medicine, Universitas Trisakti, Jakarta Barat, Indonesia

Department Clinical Pathology
How to Cite
Elitha, C., & Pusparini, P. (2020). Correlation of HbA1c and glycated albumin in hemodialysis patients with diabetes melitus. JKKI : Jurnal Kedokteran Dan Kesehatan Indonesia, 11(1), 44–51. https://doi.org/10.20885/JKKI.Vol11.Iss1.art7
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Diabetes Research and Clinical Practice. 2011;93(3):299–309.
  2. International Diabetes Federation. IDF diabetes atlas. 7th ed. Brussels: International Diabetes Federation; 2015.p.50–3.
  3. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: A report from an ADA consensus conference. Diabetes Care 2014;37(10):2864–83.
  4. Selvin E, Sacks DB. Monitoring glycemic control in end-stage renal disease: What whould be measured? Clinical Chemistry. 2017;63(2):447–9.
  5. Sany D, Elshahawy Y, Anwar W. Glycated albumin versus glycated hemoglobin as glycemic indicator in hemodialysis patients with diabetes mellitus: Variables that influence. Saudi Journal of Kidney Diseases and Transplantation. 2013;24(2):260–73.
  6. Soelistijo SA, Novida H, Rudijanto A, Soewondo P, Suastika K, Manaf A. Konsensus pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia. PB. PERKENI; 2015.
  7. Parrinello CM, Selvin E. Beyond HbA1c and glucose: The role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management. Current Diabetes Reports. 2014;14(11):548.
  8. Koga M, Kasayama S. Clinical impact of glycated albumin as another glycemic control marker. Endocrine Journal. 2010;57(9):751–62.
  9. Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: Effect of anemia and erythropoietin injection. Journal of American Society of Nephrology. 2007;18(3):896–903.
  10. American Diabetes Association. Glycemic targets. Diabetes Care. 2016;39(Suppl.1):S39–46.
  11. Kobayashi H, Abe M, Yoshida Y, Suzuki H, Maruyama N, Okada K. Glycated albumin versus glycated hemoglobin as a glycemic indicator in diabetic patients on peritoneal dialysis. International Journal of Molecular Sciences. 2016;17(5):619-25.
  12. Speeckaert M, Van Biesen W, Delanghe J, Slingerland R, Wiecek A, Heaf J, et al. Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population? Nephrology Dialysis Transplantantion. 2014 ;29(12):2167–77.
  13. Tsuruta Y, Ichikawa A, Kikuchi K, Echida Y, Onuki T, Nitta K. Glycated albumin is a better indicator of the glucose excursion than predialysis glucose and hemoglobin A1c in hemodialysis patients. Renal Replacement Therapy. 2016;2(3):1–5.
  14. Al-Maskari F, El-Sadig M, Norman JN. The prevalence of macrovascular complications among diabetic patients in the United Arab Emirates. Cardiovascular Diabetology. 2007;6:24.
  15. Bador KM, Kamaruddin SKA, Yazid NT. Brief communication (Original). Correlation of glycated albumin with self blood glucose monitoring in diabetic patients on hemodialysis taking erythropoietin. Asian Biomedicine. 2014;8(3):387–92.
  16. Gan T, Liu X, Xu G. Glycated albumin versus HbA1c in the evaluation of glycemic control in patients with diabetes and CKD. Kidney International Reports. 2018;3(3):542–54.
  17. El Sayed ZH, Ismail SM, El-hagrasy HA. Glycated albumin as a predictor of glycemic state in type 2 diabetes mellitus with chronic kidney disease. International Journal of Diabetes Research. 2018;7(3):50–6.
  18. Koga M, Murai J, Saito H, Kasayama S. Glycated albumin and glycated hemoglobin are influenced differently by endogenous insulin secretion in patients with type 2 diabetes. Diabetes Care. 2010;33(2):270–2.
  19. El Okel A, El-Arbagy A, Yassein Y, Khodir S, Kasem HS. Effect of erythropoietin treatment on hemoglobin A1c levels in diabetic patients with chronic kidney disease. Journal of The Egyptian Society of Nephrology and Transplantation. 2019;19(3):86–94.
  20. Ng JM, Cooke M, Bhandari S, Atkin SL, Kilpatrick ES. The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease. Diabetes Care. 2010;33(11):2310–3.
  21. Ningrum VDA, Ikawati Z, Sadewa AH, Ikhsan MR. Kontrol glikemik dan prevalensi gagal ginjal kronik pada pasien diabetes melitus tipe 2 di puskesmas wilayah provinsi DIY tahun 2015. Jurnal Farmasi Klinik Indonesia. 2017;6(2):78–90.
  22. Shamshirgaran SM, Mamaghanian A, Aliasgarzadeh A, Aiminisani N, Iranparvar-Alamdari M, Ataie J. Age differences in diabetes-related complications and glycemic control. BMC Endocrine Disorders. 2017;17(1):25.